Survival Benefit of Docetaxel Over Doxorubicin in Breast Cancer
SAN ANTONIO, TX -- December 13, 2007 -- Breast cancer patients who received four cycles of a docetaxel-based adjuvant regimen achieved a survival advantage compared with women who received doxorubicin-based chemotherapy, according to results from 7 years of follow up.
Read full article: http://www.docguide.com/news/content...2573B0006D1561 |
All times are GMT -7. The time now is 11:33 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021